BackProvectus Biopharmaceuticals Overview

Provectus Biopharmaceuticals Long Term Debt

Provectus Biopharmaceuticals's long-term debt is $67K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$66649.00

Peer average

Loading

Provectus Biopharmaceuticals Long Term Debt History

Loading

Provectus Biopharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Provectus Biopharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Provectus Biopharmaceuticals (PVCT) FAQ

Provectus Biopharmaceuticals (PVCT) currently reports a long-term debt of $67K as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Provectus Biopharmaceuticals's long-term debt history and peer comparisons.

Provectus Biopharmaceuticals's long-term debt changed from $0 to $67K (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Provectus Biopharmaceuticals reported $67K in long-term debt as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $67K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Provectus Biopharmaceuticals, and consider following PVCT for alerts when major investors trade the stock.

Provectus Biopharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $67K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PVCT with unrelated industries.